

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2990625

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	UGUR SAHIN	07/15/2014
	OZLEM TURECI	07/09/2014
	MICHAEL KOSLOWSKI	08/08/2014
	KORDEN WALTER	07/21/2014
	STEFAN WOLL	07/10/2014
	MARIA KREUZBERG	07/21/2014
	BERND HUBNER	07/22/2014
	MICHAEL ERDELJAN	08/19/2014
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	GANYMED PHARMACEUTICALS AG	
<b>Street Address:</b>	AN DER GOLDRUBE 12	
<b>City:</b>	MAINZ	
<b>State/Country:</b>	GERMANY	
<b>Postal Code:</b>	55131	
<b>PROPERTY NUMBERS Total: 1</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	13503461	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(312)775-8100	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	312-775-8000	
<b>Email:</b>	mhmpo@mcandrews-ip.com	
<b>Correspondent Name:</b>	MCANDREWS, HELD & MALLOY, LTD.	
<b>Address Line 1:</b>	500 W. MADISON ST.	
<b>Address Line 2:</b>	34TH FL.	
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60661	
<b>ATTORNEY DOCKET NUMBER:</b>	22741US03	
<b>NAME OF SUBMITTER:</b>	ANGELINE R. BABEL	
<b>SIGNATURE:</b>	/Angeline R. Babel/	

PATENT

<b>DATE SIGNED:</b>	08/21/2014
<b>Total Attachments: 10</b> source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page1.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page2.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page3.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page4.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page5.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page6.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page7.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page8.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page9.tif source=22741US03_342_52PCTUS_ASSIGNMENT_executed#page10.tif	

## **PATENT ASSIGNMENT**

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Wöll, Maria Kreuzberg, Bernd Hubner and Michael Erdeljan (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)" and identified as Case No. 22741US03 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on April 23, 2012, in the United States Patent and Trademark Office as Serial No. 13/503,461 as a national stage entry of International Patent Application Serial No. PCT/EP2010/06888, filed on November 11, 2010, which claims priority to European Patent Application No. 09014136.7 and U.S. Application No. 61/260,202, which were filed November 11, 2009, and European Patent Application No. 10006956.6 and U.S. Application No. 61/361,618 which were filed on July 6, 2010, and in any and all other (provisional or non-provisional) applications, both United States and foreign based thereon that claim priority thereto, which the undersigned may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and foreign countries, which may be obtained on any of said applications, and in any continuation, continuation-in-part, divisional, reexamination, renewal, substitutions, reissue, or extension of such applications or patents, and further assigns to said assignee the priority right provided by the International Convention, treaties or otherwise.

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at An der Goldrube 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid, the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.


This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]


EXECUTED this 15 day of 07, 2014.


  
\_\_\_\_\_  
Ugur Sahin


WITNESSED by  this 15 day of 07, 2014.

WITNESSED by  this 15 day of 07, 2014.  
Dr. Thomas Stanislawski

EXECUTED this 09 day of 07, 2014.

  
Özlem Türeci,

WITNESSED by  this 09 day of 07, 2014.  
Jessica Heinrich

WITNESSED by  this 09 day of 07, 2014.  
Dr. Thomas Stanislawski


EXECUTED this 8<sup>th</sup> day of Aug, 2014.

  
Michael Koslowski


WITNESSED by  this 8 day of Aug, 2014.

WITNESSED by  this 8 day of Aug, 2014.

EXECUTED this 21 day of July, 2014.


  
Korden Walter

WITNESSED by Maria Kreuzberg this 21 day of July, 2014.

WITNESSED by Thomas Karolawski this 21 day of July, 2014.  




EXECUTED this 10 day of 07, 2014.



Stefan Wöl

WITNESSED by Jessica Hein this 10 day of 07, 2014.

WITNESSED by Dr. Thomas Stanislawski this 10 day of 07, 2014.

EXECUTED this 21 day of July, 2014.

M. Kreuzberg  
Maria Kreuzberg

WITNESSED by Thomas Stanislowski this 21 day of July, 2014.

WITNESSED by [Signature] this 21 day of July, 2014.  
KORDEN CAUER

EXECUTED this 22 day of July, 2014.


Bernd Hubner  
Bernd Hubner

WITNESSED by Andrea Hedder this 22 day of July, 2014.

WITNESSED by Andrea Förster this 22 day of July, 2014.

EXECUTED this 19 day of 08, 2014.

  
Michael Erdeljan

WITNESSED by  this 19 day of 08, 2014.

Jessica Heinrich

WITNESSED by  this 19 day of 08, 2014.

Marie Krop